These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37361592)

  • 1. Chemotherapy for the initial treatment of metastatic prostate adenocarcinoma and neuroendocrine carcinoma at diagnosis: real world application and impact in the SEER database (2004 -2018).
    Wang S; Yin M; Wang P; Folefac E; Monk JP; Tabung FK; Clinton SK
    Front Oncol; 2023; 13():1165188. PubMed ID: 37361592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
    Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
    Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients.
    Hoeh B; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
    Prostate; 2021 Dec; 81(16):1374-1381. PubMed ID: 34523162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients.
    Hoeh B; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
    Front Oncol; 2021; 11():778858. PubMed ID: 34888250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.
    Zaffuto E; Pompe R; Zanaty M; Bondarenko HD; Leyh-Bannurah SR; Moschini M; Dell'Oglio P; Gandaglia G; Fossati N; Stabile A; Zorn KC; Montorsi F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2017 Oct; 15(5):e793-e800. PubMed ID: 28506524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
    Gu Y; Wu G; Zou X; Huang P; Yi L
    Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study.
    Zhu J; Liang X; Wu D; Chen S; Yang B; Mao W; Shen D
    Medicine (Baltimore); 2021 Apr; 100(15):e25237. PubMed ID: 33847621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cytoreductive surgery on outcomes of metastatic appendiceal carcinoma: a real-world, population-based study.
    Abdel-Rahman O
    J Comp Eff Res; 2020 Apr; 9(6):431-439. PubMed ID: 32253936
    [No Abstract]   [Full Text] [Related]  

  • 9. Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? A real-world study with a propensity score matching analysis.
    Pan X; Yang W; Wen Z; Li F; Tong L; Tang W
    J Gynecol Oncol; 2020 Nov; 31(6):e80. PubMed ID: 33078590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
    van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
    Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis.
    Oweira H; Petrausch U; Helbling D; Schmidt J; Mannhart M; Mehrabi A; Schöb O; Giryes A; Decker M; Abdel-Rahman O
    World J Gastroenterol; 2017 Mar; 23(10):1872-1880. PubMed ID: 28348494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.
    Cattrini C; Cerbone L; Rubagotti A; Zinoli L; Latocca MM; Messina C; Zanardi E; Boccardo F
    Clin Genitourin Cancer; 2019 Aug; 17(4):e724-e732. PubMed ID: 31160193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
    Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
    Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
    Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
    Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
    J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
    Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
    World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Site-Specific Metastases and Therapeutic Roles of Surgery and Chemotherapy for Patients With Metastatic Renal Pelvis Cancer: A SEER Based Study.
    Chen WK; Wu ZG; Xiao YB; Wang QQ; Yu DD; Cai J; Zhou CF
    Technol Cancer Res Treat; 2021; 20():15330338211004914. PubMed ID: 33929915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
    Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
    Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.
    Bandini M; Pompe RS; Marchioni M; Zaffuto E; Gandaglia G; Fossati N; Cindolo L; Montorsi F; Briganti A; Saad F; Karakiewicz PI
    Int Urol Nephrol; 2018 Jan; 50(1):71-78. PubMed ID: 29129028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy in the treatment of different histological types of appendiceal cancers: a SEER based study.
    Wang G; Li Q; Chen W
    BMC Cancer; 2021 Jul; 21(1):778. PubMed ID: 34225672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.